Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00930631 · ClinicalTrials.gov registry record · Phase 1
Study of [3H] BMS747158 in Healthy Male Subjects
A Phase 1 study, sponsored by Lantheus Medical Imaging.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT00930631 is a Phase 1 study that has completed, run by Lantheus Medical Imaging. The registered enrollment target is 7 participants.
The verdict
NCT00930631, a Phase 1 study, has completed, sponsored by Lantheus Medical Imaging.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this clinical study is to assess the safety, extent and route of \[3H\] BMS747158 radioactivity eliminated (mass balance) in urine and feces of healthy male subjects. The safety of \[3H\] BMS747158 administration will also be assessed, as well as pharmacokinetics of \[3H\] BMS747158 and metabolite identification.
Interventions
- DRUG [3H] BMS747158
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00930631
The ClinicalTrials.gov registry entry for NCT00930631 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lantheus Medical Imaging, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [3H] BMS747158 is the first listed.
NCT00930631 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00930631 about?
NCT00930631 is a clinical study titled "Study of [3H] BMS747158 in Healthy Male Subjects". The purpose of this clinical study is to assess the safety, extent and route of \[3H\] BMS747158 radioactivity eliminated (mass balance) in urine and feces of healthy male subjects. The safety of \[3H\] BMS747158 administration will also be assessed, as well as pharmacokinetics of \[3H\] BMS747158 a...
What is the current status of trial NCT00930631?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2009-06. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00930631?
The interventions under investigation include: [3H] BMS747158 (DRUG).
Who is sponsoring clinical trial NCT00930631?
This trial is sponsored by Lantheus Medical Imaging, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.